priors.science/reviews/long-covid-post-acute-sequelae

Long Covid Post Acute Sequelae

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
3 May 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 3 Likely · 8 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableNo pharmacological treatment has been approved by any major regulatory authority specifically for long COVID, and no intervention has demonstrated consistent efficacy in adequately powered randomised controlled trials.TreatmentEstablished96%6
StableA clinically significant proportion of individuals experience persistent symptoms beyond 12 weeks following acute COVID-19 infection, with estimates ranging from 5% to 20% depending on variant, vaccination status, and case ascertainment method.Prevalence EpidemiologyEstablished87%7
StableThe incidence of long COVID is substantially lower following Omicron infection compared to Delta and earlier variant infections, partly attributable to higher background vaccination coverage.Prevalence EpidemiologyEstablished87%6
StableCurrent evidence does not support routine use of anticoagulation or antiplatelet therapy for long COVID, and clinical guidelines do not recommend these agents outside of documented thromboembolic complications.TreatmentEstablished87%5
StableFemale sex, pre-existing autoimmune conditions, and higher acute COVID-19 severity are consistent independent risk factors for long COVID across multiple large cohort studies.Risk Factors ProtectionEstablished85%6
StablePost-exertional malaise (PEM) — worsening of symptoms following physical or cognitive exertion — defines a clinically distinct long COVID subgroup that overlaps with myalgic encephalomyelitis/chronic fatigue syndrome and represents a contraindication to graded exercise therapy.Symptom PhenotypesLikely83%6
StableSupervised rehabilitation programmes (including breathing exercises and pacing-based physical reconditioning) improve functional capacity and health-related quality of life in long COVID patients without post-exertional malaise.TreatmentLikely83%6
StableCOVID-19 vaccination reduces the risk of developing long COVID following breakthrough infection by approximately 40-50% compared to unvaccinated individuals with COVID-19.Risk Factors ProtectionLikely82%7
StableLong COVID in children and adolescents follows a generally milder and more self-limiting course compared to adults, with most paediatric long COVID symptoms resolving within 12 weeks.Symptom PhenotypesUncertain58%5
StablePersistent SARS-CoV-2 viral antigen or RNA in tissue reservoirs (gut epithelium, lymph nodes, adipose tissue) is detectable in a subset of long COVID patients and may drive ongoing immune activation.PathophysiologyUncertain56%6
StableCognitive impairment in long COVID (brain fog) is associated with measurable neuropsychological deficits and structural or functional brain changes on neuroimaging compared to COVID-recovered controls.Symptom PhenotypesUncertain56%6
StableSelf-reported long COVID symptom prevalence substantially overestimates the prevalence of objectively documented post-COVID organ dysfunction or impairment detectable on physiological testing.Prevalence EpidemiologyUncertain54%5
StableReactivation of latent herpesviruses (Epstein-Barr virus, cytomegalovirus) during or after acute COVID-19 is associated with long COVID development in a subset of patients.PathophysiologyUncertain50%5
StableLow-dose naltrexone may provide symptomatic benefit in long COVID through anti-neuroinflammatory and immune-modulatory mechanisms, but evidence is limited to small observational studies and preliminary trials.TreatmentUncertain47%5
StableEarly nirmatrelvir-ritonavir treatment of acute COVID-19 reduces the subsequent risk of developing long COVID symptoms in high-risk patients.Risk Factors ProtectionUncertain46%6
StablePersistent microclots and endothelial dysfunction are detectable in long COVID patients and may contribute to symptom burden including fatigue, dyspnoea, and cognitive impairment.PathophysiologyUncertain44%5
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic